Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $249M | $274M | $283M | $284M | $309M | $272M | $248M | $274M | $227M | $179M |
| Revenue growth | — | 9.9% | 3.5% | 0.2% | 8.8% | -11.9% | -9.1% | 10.7% | -17.2% | -21.1% |
| Gross profit | $79.3M | $97.8M | $95.3M | $81.2M | $89.9M | $76.9M | $76.5M | $84.8M | $69.1M | $50.2M |
| Gross margin | 31.8% | 35.7% | 33.6% | 28.6% | 29.1% | 28.3% | 30.9% | 30.9% | 30.5% | 28.1% |
| Operating income | $37.5M | $52.1M | $46.2M | $31.0M | $37.6M | $24.3M | $6.05M | -$8.16M | -$1.53M | -$58.7M |
| Operating margin | 15.0% | 19.0% | 16.3% | 10.9% | 12.2% | 8.9% | 2.4% | -3.0% | -0.7% | -32.8% |
| Net income | $23.8M | $37.3M | $37.7M | $25.9M | $30.6M | $18.7M | $5.14M | -$7.46M | -$6.27M | -$57.3M |
| Net margin | 9.6% | 13.6% | 13.3% | 9.1% | 9.9% | 6.9% | 2.1% | -2.7% | -2.8% | -32.0% |
| EPS (diluted) | $1.17 | $1.82 | $1.84 | $1.29 | $1.52 | $0.92 | $0.25 | -$0.37 | -$0.30 | -$2.74 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $47.2M | $37.4M | $45.1M | $38.8M | $40.1M | $18.5M | $27.8M | $4.32M | $4.72M | -$28.4M |
| Capital expenditures | $10.6M | $703K | $620K | $2.31M | $2.43M | $1.75M | $5.26M | $4.51M | $5.11M | $4.62M |
| Free cash flow | $36.6M | $36.7M | $44.5M | $36.5M | $37.6M | $16.7M | $22.5M | -$194K | -$395K | -$33.0M |
| Share buybacks | — | — | $0.00 | $11.5M | $0.00 | $0.00 | — | — | — | — |
| Dividends paid | $15.5M | $17.5M | $21.9M | $21.8M | $22.7M | $24.4M | $24.5M | $12.4M | $181K | $21.0K |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $58.7M | $77.9M | $101M | $104M | $119M | $111M | $104M | $55.3M | $54.7M | $21.4M |
| Total assets | $113M | $135M | $154M | $155M | $187M | $176M | $167M | $170M | $149M | $81.2M |
| Total liabilities | $19.4M | $19.1M | $19.7M | $25.3M | $46.2M | $34.1M | $57.5M | $73.2M | $63.6M | $52.3M |
| Shareholders' equity | $93.4M | $116M | $135M | $130M | $125M | $123M | $110M | $96.7M | $85.1M | $28.9M |
| Retained earnings | $86.5M | $106M | $122M | $126M | $134M | $130M | $91.7M | $71.6M | $66.5M | $9.26M |
| Shares (wtd avg diluted) | 20.4M | 20.4M | 20.5M | 20.1M | 20.1M | 20.4M | 20.3M | 20.4M | 20.6M | 20.9M |
Every figure is extracted from PETMED EXPRESS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.